June 28, 2017

The U.S. Food and Drug Administration (FDA) has granted the accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). Keytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as microsatellite […]

On a recent study that analyzed patients between 17 and 93 years of age (N = 1592), who were participants in the ECOG-ACRIN trials, the influence of the most common monosomies (5, 7, and 17) within monosomal karyotype (MK+)/complex karyotype (CK+) acute myeloid leukemia (AML) was investigated. Most MK+ patients (93%) were found to be